Eli Lilly Announces Successful Phase III Trial of Tirzepatide in Chinese Adults with Obesity or Overweight

On February 6, Eli Lilly announced that its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Tirzepatide had achieved the primary endpoint and all key secondary endpoints in the Phase III trial SURMOUNT-CN conducted in Chinese adults with obesity or overweight. In this trial, the overall safety profile of Tirzepatide was consistent with that reported in previous trials, with no new safety signals identified.

Following the groundbreaking results of SURMOUNT-1, the world's first Phase III trial of Tirzepatide for obesity or overweight reported in The New England Journal of Medicine in 2022, the SURMOUNT-CN trial has once again demonstrated positive outcomes in the Chinese population. The trial data is still being further organized and analyzed, and the relevant results will be published in a peer-reviewed academic journal.

About Tirzepatide

Tirzepatide, an innovative drug, is the world's first approved once-weekly GIP/GLP-1 receptor agonist. Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in May 2022 to improve glycemic control in adults with type 2 diabetes (in addition to diet and exercise), and has now been approved in the EU, Japan, and other countries.

Editor: Liuli

Disclaimer: This article is a reprint from Pharma Intelligence Network. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.